Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open‐angle glaucoma or ocular hypertensive patients
. Purpose: To establish the efficacy and safety of timolol maleate/dorzolamide fixed combination (TDFC) versus timolol maleate/pilocarpine fixed combination (TPFC), each given twice daily, in primary open‐angle glaucoma or ocular hypertensive patients. Methods: In this prospective, multicentred, d...
Gespeichert in:
| Veröffentlicht in: | Acta ophthalmologica Scandinavica 2003-08, Vol.81 (4), p.349-354 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 354 |
|---|---|
| container_issue | 4 |
| container_start_page | 349 |
| container_title | Acta ophthalmologica Scandinavica |
| container_volume | 81 |
| creator | Kałuz̊ny, Jakub J. Szaflik, Jerzy Czechowicz‐Janicka, Krystyna Kałuz̊ny, Józef Orzalkiewicz, Alicja Zaleska, Anna Krajewska, Malgorzata Stewart, Jeanette A. Leech, Jessica N. Stewart, William C. |
| description | .
Purpose: To establish the efficacy and safety of timolol maleate/dorzolamide fixed combination (TDFC) versus timolol maleate/pilocarpine fixed combination (TPFC), each given twice daily, in primary open‐angle glaucoma or ocular hypertensive patients.
Methods: In this prospective, multicentred, double‐masked trial, 37 patients were treated twice daily with timolol for 4 weeks. They were then randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before being placed on the opposite treatment medication for 6 weeks.
Results: A total of 36 patients completed the trial. Their mean baseline intraocular pressure (IOP) was 22.3 ± 3.7 mmHg. Following 6 weeks of treatment, the mean trough (08.00 hours) IOP was 18.0 ± 2.2 mmHg for TDFC and 17.4 ± 2.0 mmHg for TPFC (p = 0.22). The mean diurnal curve IOP was 18.1 ± 2.2 mmHg for TDFC and 16.7 ± 1.9 mmHg for TPFC (p = 0.0007). At the remaining time‐points (10.00, 18.00 and 20.00 hours), TPFC IOPs were statistically lower than TDFC IOPs (p |
| doi_str_mv | 10.1034/j.1600-0420.2003.00097.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73463199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73463199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3467-3fdbb4f549996b2ff2d2ea70fbe3c81287f8637165f0a94817d96a6b292fa6e53</originalsourceid><addsrcrecordid>eNqNkctq3TAQhkVoaG59haJNurOji2-CbkJom0AgiyRrIdujRAdZciU7PaerPkLfoW-WJ4mcc2i7KXQ1A_P9MwwfQpiSnBJenK1yWhGSkYKRnBHCc0KIqPP1Hjr8PXiTei7KjAtSH6CjGFcLRBr2Fh1Q1pSCVfQQ_bozg7feYpKXp2e9D9-9VYPpAbNTrM0aetz5oTVOTcY7_AQhzhFPf4dGY32nwmjcP0LG4TGYQYUN9iO45x8_lXuwgB-smhOnsA_Yd7NVAT9uRggTuGieAI8pDm6KJ2hfKxvh3a4eo_vPn-4uLrPrmy9XF-fXWceLqs647tu20GUhhKhapjXrGaia6BZ416SXa91UvKZVqYkSRUPrXlQqkYJpVUHJj9GH7d4x-K8zxEkOJnZgrXLg5yjrdIZTIRLYbMEu-BgDaLn7T1IiF0FyJRcPcvEgF0HyVZBcp-j73Y25HaD_E9wZScDHLfDNWNj892J5fnObGv4CHlShxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73463199</pqid></control><display><type>article</type><title>Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open‐angle glaucoma or ocular hypertensive patients</title><source>MEDLINE</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><creator>Kałuz̊ny, Jakub J. ; Szaflik, Jerzy ; Czechowicz‐Janicka, Krystyna ; Kałuz̊ny, Józef ; Orzalkiewicz, Alicja ; Zaleska, Anna ; Krajewska, Malgorzata ; Stewart, Jeanette A. ; Leech, Jessica N. ; Stewart, William C.</creator><creatorcontrib>Kałuz̊ny, Jakub J. ; Szaflik, Jerzy ; Czechowicz‐Janicka, Krystyna ; Kałuz̊ny, Józef ; Orzalkiewicz, Alicja ; Zaleska, Anna ; Krajewska, Malgorzata ; Stewart, Jeanette A. ; Leech, Jessica N. ; Stewart, William C.</creatorcontrib><description>.
Purpose: To establish the efficacy and safety of timolol maleate/dorzolamide fixed combination (TDFC) versus timolol maleate/pilocarpine fixed combination (TPFC), each given twice daily, in primary open‐angle glaucoma or ocular hypertensive patients.
Methods: In this prospective, multicentred, double‐masked trial, 37 patients were treated twice daily with timolol for 4 weeks. They were then randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before being placed on the opposite treatment medication for 6 weeks.
Results: A total of 36 patients completed the trial. Their mean baseline intraocular pressure (IOP) was 22.3 ± 3.7 mmHg. Following 6 weeks of treatment, the mean trough (08.00 hours) IOP was 18.0 ± 2.2 mmHg for TDFC and 17.4 ± 2.0 mmHg for TPFC (p = 0.22). The mean diurnal curve IOP was 18.1 ± 2.2 mmHg for TDFC and 16.7 ± 1.9 mmHg for TPFC (p = 0.0007). At the remaining time‐points (10.00, 18.00 and 20.00 hours), TPFC IOPs were statistically lower than TDFC IOPs (p < 0.03). There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC (p = 0.04). Six patients were discontinued early from TPFC therapy (17%) versus two from TDFC (6%) (p = 0.13).
Conclusions: This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open‐angle glaucoma or ocular hypertension.</description><identifier>ISSN: 1395-3907</identifier><identifier>EISSN: 1600-0420</identifier><identifier>DOI: 10.1034/j.1600-0420.2003.00097.x</identifier><identifier>PMID: 12859261</identifier><language>eng</language><publisher>Oxford, UK: Munksgaard International Publishers</publisher><subject>Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - therapeutic use ; dorzolamide ; Double-Blind Method ; Drug Combinations ; Female ; Glaucoma, Open-Angle - drug therapy ; Humans ; Intraocular Pressure ; Male ; Middle Aged ; Ocular Hypertension - drug therapy ; pilocarpine ; Pilocarpine - administration & dosage ; Pilocarpine - therapeutic use ; Prospective Studies ; Safety ; Sulfonamides - administration & dosage ; Sulfonamides - therapeutic use ; Thiophenes - administration & dosage ; Thiophenes - therapeutic use ; timolol ; Timolol - administration & dosage ; Timolol - therapeutic use ; Treatment Outcome</subject><ispartof>Acta ophthalmologica Scandinavica, 2003-08, Vol.81 (4), p.349-354</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3467-3fdbb4f549996b2ff2d2ea70fbe3c81287f8637165f0a94817d96a6b292fa6e53</citedby><cites>FETCH-LOGICAL-c3467-3fdbb4f549996b2ff2d2ea70fbe3c81287f8637165f0a94817d96a6b292fa6e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1034%2Fj.1600-0420.2003.00097.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1034%2Fj.1600-0420.2003.00097.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27922,27923,45572,45573,46407,46831</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12859261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kałuz̊ny, Jakub J.</creatorcontrib><creatorcontrib>Szaflik, Jerzy</creatorcontrib><creatorcontrib>Czechowicz‐Janicka, Krystyna</creatorcontrib><creatorcontrib>Kałuz̊ny, Józef</creatorcontrib><creatorcontrib>Orzalkiewicz, Alicja</creatorcontrib><creatorcontrib>Zaleska, Anna</creatorcontrib><creatorcontrib>Krajewska, Malgorzata</creatorcontrib><creatorcontrib>Stewart, Jeanette A.</creatorcontrib><creatorcontrib>Leech, Jessica N.</creatorcontrib><creatorcontrib>Stewart, William C.</creatorcontrib><title>Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open‐angle glaucoma or ocular hypertensive patients</title><title>Acta ophthalmologica Scandinavica</title><addtitle>Acta Ophthalmol Scand</addtitle><description>.
Purpose: To establish the efficacy and safety of timolol maleate/dorzolamide fixed combination (TDFC) versus timolol maleate/pilocarpine fixed combination (TPFC), each given twice daily, in primary open‐angle glaucoma or ocular hypertensive patients.
Methods: In this prospective, multicentred, double‐masked trial, 37 patients were treated twice daily with timolol for 4 weeks. They were then randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before being placed on the opposite treatment medication for 6 weeks.
Results: A total of 36 patients completed the trial. Their mean baseline intraocular pressure (IOP) was 22.3 ± 3.7 mmHg. Following 6 weeks of treatment, the mean trough (08.00 hours) IOP was 18.0 ± 2.2 mmHg for TDFC and 17.4 ± 2.0 mmHg for TPFC (p = 0.22). The mean diurnal curve IOP was 18.1 ± 2.2 mmHg for TDFC and 16.7 ± 1.9 mmHg for TPFC (p = 0.0007). At the remaining time‐points (10.00, 18.00 and 20.00 hours), TPFC IOPs were statistically lower than TDFC IOPs (p < 0.03). There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC (p = 0.04). Six patients were discontinued early from TPFC therapy (17%) versus two from TDFC (6%) (p = 0.13).
Conclusions: This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open‐angle glaucoma or ocular hypertension.</description><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>dorzolamide</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Humans</subject><subject>Intraocular Pressure</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ocular Hypertension - drug therapy</subject><subject>pilocarpine</subject><subject>Pilocarpine - administration & dosage</subject><subject>Pilocarpine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Safety</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - therapeutic use</subject><subject>Thiophenes - administration & dosage</subject><subject>Thiophenes - therapeutic use</subject><subject>timolol</subject><subject>Timolol - administration & dosage</subject><subject>Timolol - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1395-3907</issn><issn>1600-0420</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctq3TAQhkVoaG59haJNurOji2-CbkJom0AgiyRrIdujRAdZciU7PaerPkLfoW-WJ4mcc2i7KXQ1A_P9MwwfQpiSnBJenK1yWhGSkYKRnBHCc0KIqPP1Hjr8PXiTei7KjAtSH6CjGFcLRBr2Fh1Q1pSCVfQQ_bozg7feYpKXp2e9D9-9VYPpAbNTrM0aetz5oTVOTcY7_AQhzhFPf4dGY32nwmjcP0LG4TGYQYUN9iO45x8_lXuwgB-smhOnsA_Yd7NVAT9uRggTuGieAI8pDm6KJ2hfKxvh3a4eo_vPn-4uLrPrmy9XF-fXWceLqs647tu20GUhhKhapjXrGaia6BZ416SXa91UvKZVqYkSRUPrXlQqkYJpVUHJj9GH7d4x-K8zxEkOJnZgrXLg5yjrdIZTIRLYbMEu-BgDaLn7T1IiF0FyJRcPcvEgF0HyVZBcp-j73Y25HaD_E9wZScDHLfDNWNj892J5fnObGv4CHlShxw</recordid><startdate>200308</startdate><enddate>200308</enddate><creator>Kałuz̊ny, Jakub J.</creator><creator>Szaflik, Jerzy</creator><creator>Czechowicz‐Janicka, Krystyna</creator><creator>Kałuz̊ny, Józef</creator><creator>Orzalkiewicz, Alicja</creator><creator>Zaleska, Anna</creator><creator>Krajewska, Malgorzata</creator><creator>Stewart, Jeanette A.</creator><creator>Leech, Jessica N.</creator><creator>Stewart, William C.</creator><general>Munksgaard International Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200308</creationdate><title>Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open‐angle glaucoma or ocular hypertensive patients</title><author>Kałuz̊ny, Jakub J. ; Szaflik, Jerzy ; Czechowicz‐Janicka, Krystyna ; Kałuz̊ny, Józef ; Orzalkiewicz, Alicja ; Zaleska, Anna ; Krajewska, Malgorzata ; Stewart, Jeanette A. ; Leech, Jessica N. ; Stewart, William C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3467-3fdbb4f549996b2ff2d2ea70fbe3c81287f8637165f0a94817d96a6b292fa6e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>dorzolamide</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Humans</topic><topic>Intraocular Pressure</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ocular Hypertension - drug therapy</topic><topic>pilocarpine</topic><topic>Pilocarpine - administration & dosage</topic><topic>Pilocarpine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Safety</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - therapeutic use</topic><topic>Thiophenes - administration & dosage</topic><topic>Thiophenes - therapeutic use</topic><topic>timolol</topic><topic>Timolol - administration & dosage</topic><topic>Timolol - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Kałuz̊ny, Jakub J.</creatorcontrib><creatorcontrib>Szaflik, Jerzy</creatorcontrib><creatorcontrib>Czechowicz‐Janicka, Krystyna</creatorcontrib><creatorcontrib>Kałuz̊ny, Józef</creatorcontrib><creatorcontrib>Orzalkiewicz, Alicja</creatorcontrib><creatorcontrib>Zaleska, Anna</creatorcontrib><creatorcontrib>Krajewska, Malgorzata</creatorcontrib><creatorcontrib>Stewart, Jeanette A.</creatorcontrib><creatorcontrib>Leech, Jessica N.</creatorcontrib><creatorcontrib>Stewart, William C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta ophthalmologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kałuz̊ny, Jakub J.</au><au>Szaflik, Jerzy</au><au>Czechowicz‐Janicka, Krystyna</au><au>Kałuz̊ny, Józef</au><au>Orzalkiewicz, Alicja</au><au>Zaleska, Anna</au><au>Krajewska, Malgorzata</au><au>Stewart, Jeanette A.</au><au>Leech, Jessica N.</au><au>Stewart, William C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open‐angle glaucoma or ocular hypertensive patients</atitle><jtitle>Acta ophthalmologica Scandinavica</jtitle><addtitle>Acta Ophthalmol Scand</addtitle><date>2003-08</date><risdate>2003</risdate><volume>81</volume><issue>4</issue><spage>349</spage><epage>354</epage><pages>349-354</pages><issn>1395-3907</issn><eissn>1600-0420</eissn><abstract>.
Purpose: To establish the efficacy and safety of timolol maleate/dorzolamide fixed combination (TDFC) versus timolol maleate/pilocarpine fixed combination (TPFC), each given twice daily, in primary open‐angle glaucoma or ocular hypertensive patients.
Methods: In this prospective, multicentred, double‐masked trial, 37 patients were treated twice daily with timolol for 4 weeks. They were then randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before being placed on the opposite treatment medication for 6 weeks.
Results: A total of 36 patients completed the trial. Their mean baseline intraocular pressure (IOP) was 22.3 ± 3.7 mmHg. Following 6 weeks of treatment, the mean trough (08.00 hours) IOP was 18.0 ± 2.2 mmHg for TDFC and 17.4 ± 2.0 mmHg for TPFC (p = 0.22). The mean diurnal curve IOP was 18.1 ± 2.2 mmHg for TDFC and 16.7 ± 1.9 mmHg for TPFC (p = 0.0007). At the remaining time‐points (10.00, 18.00 and 20.00 hours), TPFC IOPs were statistically lower than TDFC IOPs (p < 0.03). There were statistically more unsolicited reports of vision change and ocular pain associated with TPFC (p = 0.04). Six patients were discontinued early from TPFC therapy (17%) versus two from TDFC (6%) (p = 0.13).
Conclusions: This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with primary open‐angle glaucoma or ocular hypertension.</abstract><cop>Oxford, UK</cop><pub>Munksgaard International Publishers</pub><pmid>12859261</pmid><doi>10.1034/j.1600-0420.2003.00097.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1395-3907 |
| ispartof | Acta ophthalmologica Scandinavica, 2003-08, Vol.81 (4), p.349-354 |
| issn | 1395-3907 1600-0420 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73463199 |
| source | MEDLINE; Wiley Free Content; Wiley Online Library All Journals |
| subjects | Antihypertensive Agents - administration & dosage Antihypertensive Agents - therapeutic use dorzolamide Double-Blind Method Drug Combinations Female Glaucoma, Open-Angle - drug therapy Humans Intraocular Pressure Male Middle Aged Ocular Hypertension - drug therapy pilocarpine Pilocarpine - administration & dosage Pilocarpine - therapeutic use Prospective Studies Safety Sulfonamides - administration & dosage Sulfonamides - therapeutic use Thiophenes - administration & dosage Thiophenes - therapeutic use timolol Timolol - administration & dosage Timolol - therapeutic use Treatment Outcome |
| title | Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open‐angle glaucoma or ocular hypertensive patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T23%3A37%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Timolol%200.5%25/dorzolamide%202%25%20fixed%20combination%20versus%20timolol%200.5%25/pilocarpine%202%25%20fixed%20combination%20in%20primary%20open%E2%80%90angle%20glaucoma%20or%20ocular%20hypertensive%20patients&rft.jtitle=Acta%20ophthalmologica%20Scandinavica&rft.au=Ka%C5%82uz%CC%8Any,%20Jakub%20J.&rft.date=2003-08&rft.volume=81&rft.issue=4&rft.spage=349&rft.epage=354&rft.pages=349-354&rft.issn=1395-3907&rft.eissn=1600-0420&rft_id=info:doi/10.1034/j.1600-0420.2003.00097.x&rft_dat=%3Cproquest_cross%3E73463199%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73463199&rft_id=info:pmid/12859261&rfr_iscdi=true |